Skip to main content
. 2015 May 8;6(24):20231–20240. doi: 10.18632/oncotarget.4047

Figure 1. Analysis of polo-like kinase 1 expression and rigosertib activity against Philadelphia (Ph)-positive leukemia cells.

Figure 1

A. Polo-like kinase 1 (PLK1) expression was examined via immunoblotting, with actin as the loading control. B., E. K562 or Ba/F3 T315I cells were treated with the indicated concentrations of rigosertib for 72 h. The percentages of cell growth were examined; *P < 0.05 compared with the control. Results represent three separate experiments. C. K562 cells were treated with the indicated concentrations of rigosertib for 48 h. Percentages of apoptotic cells were examined. These results represent three independent experiments; *P < 0.05 compared with the control. D., F. K562 or Ba/F3 T315I cells were treated with rigosertib at the indicated concentrations for 24 h. Total extracts were examined via immunoblotting with anti-phospho ABL, phospho-Crk-L, phosphohistone H2A.X, cleaved caspase 3, cleaved-PARP, ABL, Crk-L, and β-actin antibodies (abs). ABL, Abelson; PARP, poly (ADP-ribose) polymerase; abs, antibodies.